The datasets are available at Figshare: <https://figshare.com/articles/Med_TU17_CT_sav/12044346> for CT biopsies; <https://figshare.com/articles/Mediastinal_US-TCNB/12044340> for US biopsies.

Introduction {#sec006}
============

The morbidity of mediastinal tumors increases in the last 15 years and in 2014 it is 0.5/100,000 in men and 0.4/100,000 in women \[[@pone.0231523.ref001]\]. The main imaging modalities used in the evaluation of mediastinal abnormalities (chest X-ray, CT, MRI, and PET) have high sensitivity in the detection of mediastinal lesions and could give valuable information about the size, location and metabolic activity \[[@pone.0231523.ref002]\]. However, imaging and clinical evaluation often do not allow a conclusion regarding the final diagnosis in these patients. Therefore, cyto-histopathologic diagnosis is often required.

Percutaneous needle biopsy of mediastinal lesions under fluoroscopic guidance was first described in 1967 \[[@pone.0231523.ref003]\]. Since 1980 computed tomography had almost replaced fluoroscopy as a guide for a transthoracic needle biopsy (TTNB) \[[@pone.0231523.ref003]\]. CT guidance has the advantage of accurate localization of the lesion and reducing the risk of puncturing vessels in the mediastinum \[[@pone.0231523.ref004]\].

On the other hand, ultrasound (US) guidance has advantages such as real-time monitoring of the biopsy; the possibility of oblique needle paths and the ability to perform a biopsy in critically ill patients. However, the existing studies in this area are scant and with small samples.

This study aims to evaluate the diagnostic value and the complication rate of ultrasound-guided transthoracic core needle biopsy (US-TCNB), particularly large bore cutting biopsy, in patients with mediastinal lesions.

Materials and methods {#sec007}
=====================

This retrospective study includes patients evaluated between March 2004 and December 2018.

Inclusion criteria: 1. Patients with mediastinal lesions detected on thoracic CT scan; 2. Lesions more than 15 mm; 3. Patients without a histological diagnosis after bronchoscopic biopsy and transbronchial fine-needle aspiration (FNA); 4. Normal coagulation status; 5. Cooperative patient.

Exclusion criteria: 1. Uncorrectable abnormalities in coagulation: INR\>1.4; platelets \<50000/ml; aPTT \>1.5 times above the referent range.

The decision tree illustrating the diagnostic approaches to the patients included in the study is given in [Fig 1](#pone.0231523.g001){ref-type="fig"}. All patients underwent preliminary CT and US examination to localize the target lesion and to identify a safe path for needle placement. US-TCNB under real-time monitoring was carried out in all patients with mediastinal lesions suitable for US visualization. We used US system with 2D, color, Angio Doppler and contrast-enhanced imaging modalities, equipped with a sector (2.0--2.5 MHz), convex (3.5-5-7.5) MHz and linear (5--7.5--12.0 MHz) transducers, B-mode, Color, Angio and pulse wave Doppler Mode options. As acoustic windows, we used parasternal and paravertebral intercostal spaces, upper thoracic aperture and transdiaphragmal access. B-mode and color Doppler ultrasound accurately localized the tumor, clearly depicted its anatomical relations to the mediastinal vessels, the margin of the lung and the location of the internal mammary artery. The depth, location, internal structure, and size of the lesion were evaluated in B-mode images. The vascularity of the lesion was detected by color Doppler sonography.

![The decision tree illustrating the diagnostic approaches to the patients included in the study.\
Abbreviations: ML: mediastinal lesions; MLy: malignant lymphoma; CT: computed tomography; US: ultrasound; US-TCNB: US-guided transthoracic needle biopsy; CT-TTNB: CT guided transthoracic needle biopsy; SP: surgical procedures.](pone.0231523.g001){#pone.0231523.g001}

Different US-guided biopsy techniques were used, as follow: (a) Attachable stretcher guides that can be fit to the transducers, directing the needle to various depths from the transducer, depending on the angle set by the operator; (b) \"Free hand\" technique: the needle can be inserted through the skin directly into the plane of view of the transducer. During the US-TCNB the echogenic needle tip was guided to the target by B-mode sonography and a 'twinkling sign' on color Doppler imaging \[[@pone.0231523.ref005]\] (Figs [2](#pone.0231523.g002){ref-type="fig"} and [3](#pone.0231523.g003){ref-type="fig"}).

![A. Color Dopler US imaging: a "twinkling sign" with visualization of the biopsy needle during its manual movement (arrow). B. Color Dopler US-imaging supraclavicular approach, convex probe 3.5 MHz: Enlarged upper paratracheal lymph nodes (R2). US-TCNB (18G): The biopsy needle placed into the target mediastinal lesion (arrow).](pone.0231523.g002){#pone.0231523.g002}

![A. CT scan: Large mediastinal lesion in the anterior-superior compartment. B. Real-time Virtual Sonography (RVS) fusion imaging technology CT/ US Color Doppler (CD) imaging, left site parasternal approach (transversal section), with a convex probe 2.5--5.0 MHz: Visualization of a. thoracica int. sin. (yellow arrow), the biopsy needle (18G) placed across the thoracic wall. C. Biopsy needle into the tumor mass (blue arrow marks the apex). D. Twinkling sign (CD phenomenon) marks the needle.](pone.0231523.g003){#pone.0231523.g003}

In the first 125 patients, US-TCNB was preceded by ultrasound-guided transthoracic fine-needle aspiration (US-TFNA) for evaluation of diagnostic value between the methods. US-TFNA was carried out using a 22 G Chiba needle.

The parasternal approach was used for US-TCNB biopsy in patients with anterior-superior mediastinal lesions. The same approach may be utilized in rare cases with lesions in middle mediastinum surrounded by atelectatic pulmonary parenchyma. The internal mammary artery was evaluated by color Doppler sonography to avoid being affected during the biopsy ([Fig 3](#pone.0231523.g003){ref-type="fig"}). The internal mammary vessels located on either side of the sternum may have a significant variation in the position \[[@pone.0231523.ref006]\]. A suprasternal or supraclavicular approach through the paratracheal soft tissue space was used to detect lesions located in the upper mediastinum. If possible, the patients were in a supine position with a pillow below the scapulas to keep the neck maximally extended. The paravertebral approach was used for biopsy of posterior mediastinal lesions. All patients with mediastinal lesions unsuitable for US visualization were evaluated for a CT-guided TTNB (CT-TTNB). The CT guiding was done using a CT system General Electric Bright Speed, 0.75 s gantry rotation time, 100--120 kV, 50--80 mA, 5 mm collimation. In a parasternal approach, the needle is inserted lateral to the sternum and advanced through the chest wall and mediastinal fat into the target lesion. CT scans were obtained between steps of needle advancements to check the trajectory and ensure that the mediastinal vessels are not in the needle path. A direct mediastinal approach, which allows extrapleural needle placement, was the preferred method of US/CT-TTNB to avoid the risk of pneumothorax.

US/CT-TCNB was performed using large-bore (14G) or small-bore (18G) automatic histologic needles with a length of 100--200 mm. All image-guided TTNB were performed under local anesthesia, using a 10 ml 1% solution of Lidocaine. The patients were followed up at least 3 hours after the procedure to ensure their hemodynamic stability and to monitor their respiratory status. In all patients chest X-ray and control US examination were obtained 2 hours after the biopsy. US-TFNA samples were pathologically and microbiologically examined, including hematoxylin-eosin (HE), acid-fast, and Gram stains or bacterial cultures in case of clinical suspicion. Special histologic staining methods including immunohistochemical techniques were applied.

All patients inappropriate for image-guided TTNB were referred for primary surgical diagnostic procedures. The patients with benign mediastinal lesions, those with malignancies considered as resectable and patients with uninformative results according to US-TCNB and CT-TTNB were referred to secondary surgical procedures ([Fig 1](#pone.0231523.g001){ref-type="fig"}).

The definitive diagnosis was verified by histopathological examination of a tissue sample obtained through image-guided TCNB, primary and secondary surgical procedures. All results from the US/CT-TTNB techniques were subsequently reviewed and compared with the definitive diagnosis. Sensitivity, specificity, positive and negative predictive values and diagnostic accuracy of the method were estimated by standard formulas.

Statistical analysis was performed using commercially available software (Microsoft Excel; Microsoft Corp. and SPSS Statistic 17; SPSS Inc.). The data from the study was processed with methods of descriptive statistics. A chi-square test was used to determine the associations between categorical variables. Continuous variables were examined for normality by the Shapiro-Wilk test. For normally distributed variables, differences between the groups were determined by independent-samples T-test. Mann-Whitney U test was used for abnormally distributed variables. A P-value of 0.05 was considered significant.

The Clinical Center for Pulmonary Diseases Ethical Committee approved the study and all patients provided written informed consent for the procedure (number 48/16.08.2017). All the information is processed anonymously.

Results {#sec008}
=======

A total of 566 patients with mediastinal lesions above 15 mm in diameter (mean 55.4 ± 19 mm, minimum 15 mm, maximum 160 mm), suspicious of malignancy were evaluated, 306 (54%) were males and 260 (46%) were females, mean age 46.8 ± 16.8 years. The mediastinal lesions were localized according to the surgical division of the mediastinum into compartments ([Fig 4](#pone.0231523.g004){ref-type="fig"}) \[[@pone.0231523.ref005]\].

![Distribution of the patients according to the localization of mediastinal lesions.\
Surgical division of the mediastinum into compartments: A-S---anterior-superior mediastinal compartment; M---Middle mediastinal compartment; P---posterior mediastinal compartment.](pone.0231523.g004){#pone.0231523.g004}

US visualization of the mediastinal lesions was successful in 308 (54.4%) patients, with the highest success ratio (84%) for the lesions located in the anterior-superior compartment ([Fig 4](#pone.0231523.g004){ref-type="fig"}). In all of them, US-TCNB was performed. The US guidance of TTNB allowed real-time continuous monitoring of the needle during advancement and sampling. The color Doppler US imaging allowed great vessels, collaterals and tumor vessels to be demonstrated clearly, and the biopsy route could be preselected to avoid puncturing them and as much as possible to prevent complications (Figs [2](#pone.0231523.g002){ref-type="fig"} and [3](#pone.0231523.g003){ref-type="fig"}). The parasternal approach ([Fig 3](#pone.0231523.g003){ref-type="fig"}) was used for US-TCNB biopsy in 247 (80.2%) patients: 245 of them with anterior-superior mediastinal lesions and 2 patients with middle mediastinum lesions visualized through atelectatic lung parenchyma. There were 38 patients for whom US-TCNB through supraclavicular and suprasternal approach was considered safe (12.3%, [Fig 2](#pone.0231523.g002){ref-type="fig"}). The paravertebral approach was used for biopsy of posterior mediastinal lesions in 23 patients (7.5%). The distribution of patients according to the localization of the mediastinal lesions and the type of performed image-guided TTNB procedure is presented in [Table 1](#pone.0231523.t001){ref-type="table"}.

10.1371/journal.pone.0231523.t001

###### Distribution of the patients according to the localization of ML and the type of performed image-guided transthoracic needle biopsy.

![](pone.0231523.t001){#pone.0231523.t001g}

  Methods of biopsy        A-S comp.   Middle comp.   Posterior comp.   Dimensions Min/ Max $\overline{X}$ ± SD   TTNB passes $\overline{X}$
  ------------------------ ----------- -------------- ----------------- ----------------------------------------- ----------------------------
  US-TCNB (n = 308)        283         2              23                15 / 160 mm                               
                           216         0              12                57 ± 20 mm                                1.26
  14G (n = 228)            67          2              11                52 ± 20 mm                                2.0
  18G (n = 80)             114         1              10                52.5 ± 15 mm                              2.0
  US-FNA (n = 125)                                                      (p\>0.05)                                 
  CT-TTNB (18G) (n = 31)   15                         16                20 / 85 mm                                1.1
  CT-FNA (n = 10)                      10                               50± 13 mm (p\>0.05)                       2.0

Abbreviations: TTNB: transthoracic needle biopsy; US-TCNB: US-guided transthoracic core needle biopsy; US-FNA: US-guided transthoracic fine-needle aspiration; CT-TTNB: CT-guided transthoracic core needle biopsy; CT-FNA: CT-guided fine-needle aspiration; A-S comp.: anterior-superior mediastinal compartment.

We performed a single pass, large-bore (14G) US-TCNB in 228 patients. In 54 of them, we repeated the biopsy due to not good quality tissue obtained, and in 3 patients we had to do the procedure for the third time. A total of 288 14G US-TCNB were performed in 228 patients (1.26 procedures per patient).

Small-bore (18G), two passes US-TCNB were carried out in 80 patients. We did not establish a statistically significant difference in dimensions of mediastinal lesions biopsied with 14G and 18G true cut needles ([Table 1](#pone.0231523.t001){ref-type="table"}; p\>0.05).

At the time of presentation 113 (20%) patients had superior vena cava syndrome (SVC). We succeeded in ultrasound visualization of the target lesion in 85 (75.2%). In this high-risk group, a single pass 14G (n = 53) and two passes 18G (n = 32) US-TCNB were performed. In 22 critically ill patients with severe dyspnea who cannot tolerate a supine position, US guidance provided us with an opportunity to perform TCNB biopsy in sitting or semi-sitting positions.

US-TCNB (14G or 18G) in patients with mediastinal lesions provided an informative tissue sample, which allowed establishing a correct histological diagnosis in 95.8% (295/308) of them.

The final diagnoses according to the histological results from US-TCNB and confirmed by surgical procedures are listed in [Table 2](#pone.0231523.t002){ref-type="table"}. In 1 patient the diagnosis of malignant thymoma, achieved by US-TCNB was subsequently revised following the histological result of a surgical biopsy (thoracotomy) in Hodgkin's lymphoma. In 13 patients (4.2%) US-TCNB/FNA specimens were uninformative and the diagnosis was established through: thoracotomy (n = 5); VATS (n = 7); US-TCNB of supraclavicular lymph node (n = 1). The definitive diagnoses were: Hodgkin\`s lymphoma (n = 5); large B-cell lymphoma (n = 3); lymphoblastic lymphoma (n = 1); malignant thymoma (n = 2); malignant mesenchymal tumor (n = 1); metastatic small cell lung cancer (n = 1).

10.1371/journal.pone.0231523.t002

###### Histological diagnosis of mediastinal lesions according to the results of US-TCNB, confirmed by surgical procedures (n = 308).

![](pone.0231523.t002){#pone.0231523.t002g}

  Diagnosis                               Number of patients   Percent (%)
  --------------------------------------- -------------------- -------------
  Hodgkin's lymphoma                      62                   20.1
  Thymoma                                 43                   14.0
  Benign mesenchymal tumors               35                   11.4
  Diffuse large B-cell lymphoma           33                   10.7
  Metastasis from SCLC                    33                   10.7
  Metastasis from NSCLC                   26                   8.4
  Other types of non-Hodgkin lymphomas    21                   6.8
  Malignant mesenchymal tumors            18                   5.8
  Metastasis from extrathoracic tumors    9                    2.9
  Malignant germ cell tumor               5                    1.6
  Carcinoid tumor                         4                    1.3
  Mediastinal teratoma                    2                    0.6
  Substernal thyroid goiter               2                    0.6
  Malignant neurogenic tumor              1                    0.3
  Intrathoracic thyroid gland carcinoma   1                    0.3
  Uninformative result                    13                   4.2
  Total                                   308                  100%

The accuracy of all US-TCNB for the diagnosis of malignant mediastinal lesions was 95.8% (295/308) ([Table 3](#pone.0231523.t003){ref-type="table"}). The diagnostic value of US-TCNB in special clinical conditions and by type of the mediastinal lesion is given in [Table 3](#pone.0231523.t003){ref-type="table"}. There is no significant difference in accuracy between 14G and 18G US-TCNB. We did not find a reliable difference in the accuracy of the US-TCNB between subgroups patients with and without SVC and/or mediastinal syndrome (94.1% vs. 96.4%, p\>0.25).

10.1371/journal.pone.0231523.t003

###### Diagnostic value of all minimally invasive methods.

![](pone.0231523.t003){#pone.0231523.t003g}

  Method                                                                       Acc, %   Se, %   Sp, %   PPV, %   NPV, %
  ---------------------------------------------------------------------------- -------- ------- ------- -------- --------
  US-TCNB (n = 308)                                                            95.8     95.1    100     100      75
  \- 14G true cut (n = 228)                                                    95.6     94.9    100     100      75.6
  \- 18G true cut (n = 80)                                                     96.5     95.8    100     100      72.7
  US-TCNB in special clinical conditions and types of the mediastinal lesion                                     
  SVC syndrome (n = 85)                                                        94.1     94      100     100      28
  Malignant lymphoma (n = 124)                                                 97       93      100     100      95.3
  Metastatic ML (n = 66)                                                       99.7     98.5    100     100      99.6
  Malignant thymoma (n = 36)                                                   99       95.6    99.6    97.7     99.2
  US-FNA (n = 125)                                                             76       73      94      98       37
  CT-TTNB (n = 41)                                                             90       90      100     100      33
  Image-guided (US and CT) TCNB (n = 339)                                      95.3     94.6    100     100      72

Abbreviations: TTNB---transthoracic needle biopsy; US-TCNB---US-guided transthoracic core needle biopsy; US-FNA---US-guided transthoracic fine-needle aspiration; CT-TTNB---CT-guided transthoracic needle biopsy; n- number of patients; SVC---superior vena cava syndrome; ML mediastinal lesions. Acc---accuracy; Se---sensitivity; Sp---specificity; PPV---positive and NPV---negative predictive value.

There was no significant difference in dimensions of mediastinal lesions biopsied under US and CT control ([Table 1](#pone.0231523.t001){ref-type="table"}; p = 0.23). The accuracy of CT-TTNB was 90% ([Table 3](#pone.0231523.t003){ref-type="table"}). We did not establish a significant difference in accuracy between groups patients with US-TCNB and CT-TTNB.

The cytology examination of the US-TFNA specimen established a correct diagnosis in 78 patients (62.4%). In our study US-TFNA had high diagnostic accuracy for epithelial metastatic disease, establishing a correct diagnosis in 94% (32/34). US-TFNA specimen was guiding to the diagnosis in 65% (32/49) of cases with malignant lymphoma and 58% (14/24) of cases with thymoma. However, the accuracy of US-TFNA was significantly lower compared to US-TCNB (76% vs. 95.8%, p\<0.001; [Table 3](#pone.0231523.t003){ref-type="table"}).

The diagnostic value of all types of primary and secondary surgical procedures performed in patients with mediastinal lesions is presented in [Table 4](#pone.0231523.t004){ref-type="table"}. The accuracy of all surgical procedures (n = 271) was 98.4%, sensitivity 98.2%, specificity 100%, positive predictive value 100% and negative predictive value 88.6%. There was no significant difference in the accuracy of the US-TCNB (n = 308) when compared to all surgical procedures (n = 318) (95.8% vs. 98.4%, p\>0.1), but there is significant difference in accuracy between all image-guided (US and CT, n = 339) TCNB and all surgical procedures (p\<0.025).

10.1371/journal.pone.0231523.t004

###### Distribution of the patients according to the performed surgical procedures.

![](pone.0231523.t004){#pone.0231523.t004g}

  Surgical procedures   VATS   TT    AMT    MSc    Sum SP
  --------------------- ------ ----- ------ ------ --------
  Primary SP            169    25    2      21     217
  Secondary SP          23     53    19     6      101
  Total number          192    78    21     27     318
  Acc, %                98.4   100   95.3   96.3   98.4
  Se, %                 98.2   100   95     96.2   98.2
  Sp, %                 100    100   100    100    100
  PPV, %                100    100   100    100    100
  NPV, %                87     100   50     50     88.6

Abbreviations: VATS---video-assisted thoracoscopic surgery; TT---thoracotomy; AMT---anterior mediastinotomy; MSc---mediastinoscopy; SP---surgical procedures. Acc---accuracy; Se---sensitivity; Sp---specificity; PPV---positive and NPV---negative predictive value.

We observed complications of US-TCNB in 8 (2.6%) patients: 2 cases of partial pneumothorax, 1 of them needed pleural drainage with 3-day hospitalization; 3 patients with chest wall hematoma spontaneously resolved, 2 with collapses due to vasovagal reactions, 1 with non-massive hemoptysis. The complication rate did not depend on the size of biopsy needles: 14G (5/228) or 18G (3/80), p\>0.10.

We found out complications risk of CT-TTNB 14.6% (6 patients): 3 cases of partial pneumothorax, 1 of them needed pleural drainage with 3-day hospitalization; 1 patient with a small amount of hemoptysis; 2 patients with collapses due to vasovagal reactions. The complication rate of US-TCNB was significantly lower than the complication rate of CT-TCNB (p\<0.001).

Discussion {#sec009}
==========

Since *Saito* et al. showed 82% diagnostic yield of US-TCNB in a small sample of 11 patients, there is growing interest in this procedure \[[@pone.0231523.ref007]\]. *Sawhney* et al. described the use of large cutting needles for mediastinal biopsies in selected patients \[[@pone.0231523.ref008]\].

In our study, US-TCNB was an appropriate diagnostic method in 54% of the patients with mediastinal lesions, especially when lesions were located in the anterior-superior mediastinal compartment (success rate of US visualization 84%). We did not establish a significant difference between the accuracy of US-TCNB and CT-TTNB. Our results correspond to the data of published studies in which the sensitivity of CT-TTNB varies between 70--94% with negative predictive value 35--55% \[[@pone.0231523.ref009],[@pone.0231523.ref010]\] and complication rate 16--45% \[[@pone.0231523.ref011]\]. CT guidance has the advantage of accurate localization of the lesion, especially in cases invisible by US, thus the hazard of puncturing vessels in the mediastinum could be avoided \[[@pone.0231523.ref004]\]. However, CT-TTNB showed a higher incidence of iatrogenic complications when compared to US-TCNB. The additional disadvantages of CT-TTNB were higher cost, radiation exposure, and step by step control of the procedure.

The advantages of US guidance include: effective real-time monitoring of the biopsy; the color Doppler allows the vascularity of the lesion to be evaluated and vascular structures to be avoided as much as possible to prevent possible complications; the opportunity of changing needle slope during the biopsy procedure; the ability to perform a biopsy in critically ill patients including those with dyspnea in forced semi-sitting or sitting positions (not possible with CT guidance). In patients with SVC syndrome, a condition in which surgical diagnostic procedures carry a high risk of bleeding, respiratory distress, and airway compression, US-TCNB is highly effective and has the lowest complication rate \[[@pone.0231523.ref012]--[@pone.0231523.ref014]\].

The small-bore TCNB also provided high-quality histopathologic specimens adequate for histologic diagnosis in most cases. There is no significant difference in accuracy between subgroups with 14G and 18G US-TCNB. The US-TCNB was highly effective in verifying all diagnostic subgroups: malignant lymphoma, thymoma, metastatic mediastinal engagement. The complications of US-TCNB were mild, non-life threatening and did not depend on the size of the biopsy needle.

*Koegelenberg* et al. performed US-TFNA (n = 45) with rapid on-site evaluation followed by US-TCNB in undiagnosed cases \[[@pone.0231523.ref015]\]. This approach yielded similar diagnostic value: an accurate cytological diagnosis was made in 33 (73.3%), and was more likely to be diagnostic in epithelial carcinoma and tuberculosis (28/30) than all other pathologies (5/15). In our study, the accuracy of the US-FNA biopsy was comparable (76%). Despite advances in cytopathologic techniques, such as flow cytometry, immunohistochemical phenotyping, and gene rearrangement studies, the role of FNA in the diagnosis of lymphoma, thymoma, germ cell tumors, neurogenic tumors, and benign tumors remains controversial.

Our data suggest that US-TCNB should be a preferable method for histological verification of mediastinal lesions, especially for those located in the anterior-superior compartment. US-FNA biopsy is applied in high-risk patients alone or most often as an assistant method, tracing the safe path of the cutting needle to the target lesion.

Surgical procedures have accuracy up to 100% and in some cases could simultaneously establish the diagnosis and provide treatment \[[@pone.0231523.ref002],[@pone.0231523.ref016]--[@pone.0231523.ref021]\]. All surgical procedures usually require hospitalization, general anesthesia and have a higher cost. Not least, complications are observed in 3--16% of patients \[[@pone.0231523.ref002],[@pone.0231523.ref017]--[@pone.0231523.ref026]\].

To the best of our knowledge, this is by far the biggest study that examines the diagnostic yield and complication rate of US-TCNB in patients with mediastinal lesions. It shows the possibility of noninvasive histological diagnosis of mediastinal lesions while at the same time examines the complication rate. Moreover, it could be used in critically ill patients, including those with SVC syndrome.

The major limitation of US-TCNB was the absence of the 'acoustic window', observed in 46% of our patients.

Conclusion {#sec010}
==========

US-TCNB is a highly effective and safe diagnostic tool for mediastinal lesions in all nosological groups. According to the accuracy, it is non-inferior to the CT-guided needle biopsy and comes close to the effectiveness of surgical biopsy techniques, but has significantly lower complication rate. It is the method of choice in critically ill patients, including those with SVC syndrome, especially when is necessary to perform a biopsy in forced semi-sitting or sitting position.

10.1371/journal.pone.0231523.r001
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Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This paper analyzes the diagnostic value and the complication rate of US-TCNB, particularly large bore cutting biopsy in patients with mediastinal lesions. The authors show that US-TCNB of mediastinal lesions is highly effective and safe tool which is

particularly helpful in critically ill patients. This article is not innovative. There are several issues that make this concept as currently presented unconvincing:

1\. Inclusion criteria should be described in details. For example, why chose only dimension of the lesions more than 15 mm.

2\. Characteristics of participants should be described, such as age, lesion location, size of lesion.

3\. Study patients by diagnosis should be also described in details.

4\. In lines 259-264, the result is inconvincible. The details of US-guided CNB including or excluding insufficient samples should be described. What about the positive predictive and the negative predictive?

5\. The figure legends and tables should be moved to the end of the paper. Moreover, the tables is difficult to read and should be modified.

6\. The manuscript needs more work on improving the English and the clarity and focus of the presented arguments.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0231523.r002

Author response to Decision Letter 0

28 Jan 2020

Dear Dr. Alizad,

Thank you and the Reviewers for the constructive feedback provided. I had tried to address the pointed issues and feel the manuscript is significantly improved. I am uploading a revised version with revisions in "track changes". I have responded to the reviewers' comments below in bold.

Kind regards,

Evgeni Mekov

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

We've tried to comply with all of the journals' requirements. Please also note that the above links are not active. However, if there is still an issue we apologize and we are ready to resolve it upon request.

In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them. If patients provided informed written consent to have data from their medical records used in research, please include this information.

All the information is processed anonymously. The manuscript is edited to include this answer.

We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. \[\"Paper is containing original research and has not been submitted/published earlier in any journal and is not being considered for publication elsewhere. However there are 4 ABSTRACTS presented at the European Respiratory Congresses: \... They are not full text publications, nor is this manuscript submitted for consideration anywhere else. These are presentations of the work only in abstract form.\"\] Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

Several abstracts are presented on congresses. These include a part of the results. These papers are not peer-reviewed per se:

\- Usually, they are reviewed by 1 person who rates them on a scale and based on the results they are accepted or rejected;

\- Writing a review is not required for this type of evaluation;

\- They are not handled by at least two peers, nor are they handled by an academic editor;

\- We didn't fill the copyright agreement form;

\- Moreover, they are less than 400 words and are not considered a full-text publication.

However, the ERS representative could give you more information if there is still an issue on this topic. As a rule, the majority of the researchers present their work at congresses and subsequently publish it as a full text.

We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

I confirm uploading raw data upon acceptance.

Reviewers\' comments:

Reviewer \#1: This paper analyzes the diagnostic value and the complication rate of US-TCNB, particularly large bore cutting biopsy in patients with mediastinal lesions. The authors show that US-TCNB of mediastinal lesions is highly effective and safe tool which is particularly helpful in critically ill patients. This article is not innovative. There are several issues that make this concept as currently presented unconvincing:

1\. Inclusion criteria should be described in details. For example, why chose only dimension of the lesions more than 15 mm.

Lesions less than 15 mm are deemed unsuitable for US-TCNB because of increased risk of iatrogenic complications. The cutting diameter of this type of needles is 20 mm, therefore even 15 mm lesions possess a significant risk of complication even if they are placed at the optimal position because they will cut more than a maximal lesion diameter. However, we could manage this issue by cutting the tissues of the chest wall (e.g. muscle tissue) rather than lung parenchyma. We don't have experience with lesions \<15 mm, but we don't recommend this technique in these cases.

The other criteria are self-explanatory, we need cooperative patients (some cases require holding breath, e.g. when the lesion is moving or behind the rib, etc), normal coagulation is required in any type of biopsy. Bronchoscopy is a standard diagnostic procedure and is performed in every patient with such lesions. Moreover, it is required preoperatively. If there are other queries or issues we could discuss them.

2\. Characteristics of participants should be described, such as age, lesion location, size of lesion.

Lesion location and size are described in table 2. The age is described in the paper (page 9, row 171, 172).

3\. Study patients by diagnosis should be also described in details.

Study patients by diagnosis are described in table 2.

4\. In lines 259-264, the result is inconvincible. The details of US-guided CNB including or excluding insufficient samples should be described. What about the positive predictive and the negative predictive?

I am not sure I understand you properly what is your query. Insufficient samples by means of undiagnostic samples should be included as a part of false negatives. Otherwise, please specify.

5\. The figure legends and tables should be moved to the end of the paper. Moreover, the tables is difficult to read and should be modified.

According to the submission guidelines, they should stay as is. This is an excerpt from <https://journals.plos.org/plosone/s/submission-guidelines>:

Other elements:

\- Figure captions are inserted immediately after the first paragraph in which the figure is cited. Figure files are uploaded separately.

\- Tables are inserted immediately after the first paragraph in which they are cited.

Regarding the difficulty, could you please be more specific about this particular issue? What table could eventually imply difficulty to modify it for the readers?

6\. The manuscript needs more work on improving the English and the clarity and focus of the presented arguments

The manuscript is edited as suggested

I would like to thank you and reviewers for the helpful feedback.

10.1371/journal.pone.0231523.r003
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26 Mar 2020
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PONE-D-19-21908R1

Dear Dr. Mekov,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Azra Alizad, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for addressing the comments of previous reviews. It is a great work.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: I have no additional comments. The authors have done a good job addressing the previous reviews. Thank you

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

10.1371/journal.pone.0231523.r004
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31 Mar 2020

PONE-D-19-21908R1

Diagnostic value and complication rate of ultrasound-guided transthoracic core needle biopsy in mediastinal lesions

Dear Dr. Mekov:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Azra Alizad

Academic Editor

PLOS ONE
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